Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience

Pediatric Blood and Cancer

Volumn 64, Issue 4, 2017, Pages

  Marsh, Rebecca A ^a   Jordan, Michael B ^a   Talano, Julie An ^b   Nichols, Kim E ^c   Kumar, Ashish ^a   Naqvi, Ahmed ^d   Vaiselbuh, Sarah R ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

hemophagocytic lymphohistiocytosis; HLH; refractory HLH; salvage therapy

Indexed keywords

ALEMTUZUMAB; ANAKINRA; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; BACTEREMIA; BONE MARROW TOXICITY; CANDIDEMIA; CHILL; CYTOPENIA; DEATH; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS INFECTION; FEVER; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFECTION; INFECTIOUS COMPLICATION; LYMPHOPROLIFERATIVE DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PYRAMIDAL IRRITATION; PYRAMIDAL SIGN; REFRACTORY DISEASE; REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; REMISSION; REVIEW; SALVAGE THERAPY; SEIZURE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; VIREMIA; VIRUS REACTIVATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PROGNOSIS;

DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PROGNOSIS; SALVAGE THERAPY;

EID: 84999791337     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26308     Document Type: Review

References (23)

1. Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–4052.
2. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957–1959.
3. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003;115(4):461–473.
4. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14(6):827–834.
5. zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009;85(4):482–492.
6. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173–176.
7. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14(3):307–311.
8. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20(2):129–135.
9. Nichols KE, Harkin DP, Levitz S, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA. 1998;95(23):13765–13770.
10. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395(6701):462–469.
11. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444(7115):110–114.
12. Bode SF, Ammann S, Al-Herz W, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015;100(7):978–988.
13. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–2373.
14. Mahlaoui N, Ouachee-Chardin M, de Saint Basile G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics. 2007;120(3):e622–e628.
15. Marsh RA, Allen CE, McClain KL, et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer. 2013;60(1):101–109.
16. Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186–2192.
17. Behrens EM, Kreiger PA, Cherian S, et al. Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J Rheumatol. 2006;33(10):2081–2084.
18. Miettunen PM, Narendran A, Jayanthan A, et al. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011;50(2):417–419.
19. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol. 2010;7(7):415–420.
20. Gerard LM, Xing K, Sherifi I, et al. Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. Int J Hematol. 2012;95(4):445–450.
21. Jordan M, Locatelli F, Allen C, et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH. Blood. 2015;126:LBA-3 [abstract].
22. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016;127(13):1666–1675.
23. Maschalidi S, Sepulveda FE, Garrigue A, et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016;128(1):60–71.